Bakers did not get crushed they sold 25% many months ago and shorted in the meantime. They were the strongest signal that it was in trouble ..FORGET this board as clowns will taunt Lawyers will be here and XOMA will go back to 2 dollar land.
For the last month trading shows the short position has been covering. This morning they took out the stops.
The Bakers and the shorts could have easily hedged with the volume of the last 6 months so I nor anyone here can be sure of the outcome but they wont lose money. I dont have to tell anyone who has followed XOMAs 20 yr history of many disappointments and that includes last years Phase2 trial. Most biotech investors who saw the initial eyeguards Phase2 results had a Wow!... and the ODDS favor meeting the endpoint. 55-70% say analysts ( gutsy eh?) . Verifying the pipeline will finally take XOMA out of the top 10 most hated bios to a darling and double digits in a flash Good Luck
Journal of Surgical Oncology Publishes Study Showing Oncotype DX Score(TM) Result Changes Treatment
Physicians Ranked Oncotype DX DCIS Score Most Important Factor in Treatment Planning
following me around - ignore and dont engage. TIA
Results Presented at AACR Demonstrate Company's Ability to Monitor Bladder Cancer Using Non-Invasive
blood test .... on market in 2016
You can assess nothing from "the street" on such a thinly traded stock. The company is completely controlled by its investors who understand the GHDX value. They don't care what the price is today. A stock with a price less than 3 times revenues and no debt with expanding markets is held up for only one reason. The BOD meets next week. Good Luck
Oncotype DX at ASCO in Breast and Prostate Cancer Reinforce Genomic Health's Leadership in Optimizing Cancer Treatment
New Data Include Two Positive Studies in DCIS Breast Cancer and Report of Baseline Characteristics in NCI's TAILORx Trial Examining Oncotype DX across Race and Ethnicity
announced results from multiple Oncotype DX studies presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting. The presentations reinforce the robustness of the Oncotype DX tests across invasive breast cancer, ductal carcinoma in situ (DCIS) and prostate cancer, which, to date, have helped guide treatment decisions for more than half a million patients worldwide.
Two DCIS Studies Reinforce Independent Value of Oncotype DX DCIS Score™
A secondary analysis from the second large validation study conducted by the Sunnybrook Health Sciences Centre in Ontario evaluated the DCIS Score™ result as a predictor of local recurrence in 718 patients treated with breast-conserving surgery (BCS) alone with any surgical margin width. The analysis showed that, in all patients regardless of margin status, the DCIS Score result was significantly associated with the 10-year risk of local recurrence (p < 0.001). These results underscore the value of the DCIS Score result in providing unique tumor biology information that is not readily apparent by margin status alone.
A separate secondary analysis evaluated the correlation between the DCIS Score result and clinicopathologic features, such as age, tumor size, nuclear grade and multifocality. The results from 571 women with DCIS who had BCS alone and clear margins showed that the DCIS Score result quantifies risk of local recurrence independent of clinicopathologic features, reconfirming previous findings from the ECOG-ACRIN Cancer Research Group clinical validation study.
yes , for what indication ? - )) GHDX prostate and breast cancer test will be on market next year.Good luck to BIOC and their data results in the future
Multiple Oncotype DX(R) Presentations at the American Society of Clinical Oncology Annual Meeting Highlight Genomic Health's Leadership in Personalizing Breast, Prostate Cancer Care
" results from four Oncotype DX® studies will be presented at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place May 29-June 2 at McCormick Place in Chicago. abstracts are now available at asco abstracts site
Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, Chief Operating Officer and Chief Financial Officer, will present at the Jefferies 2015 Global Healthcare Conference in New York City on Monday, June 1 at 8:30 a.m. Eastern Time (ET).
To access the live and subsequently archived webcast of the presentation, go to the Investor Relations section of the company's web site
352k cover this morning .... I suspect GHDX will get the top notch covering as they did in Europe ( NICE ) .... I found that interesting that Polaris didnt get it.
The draft LCD is posted to the Medicare Coverage Database on the Centers for Medicare and Medicaid Services (CMS) website. It will go through Medicare's review process, which includes a public comment period, finalization and notification....................
today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a draft local coverage determination (LCD) for the Oncotype DX prostate cancer test. The draft LCD recommends coverage of the Oncotype DX prostate cancer test for qualified Medicare patients throughout the United States "to help determine which patients with early-stage, needle biopsy proven prostate cancer, can be conservatively managed rather than treated with definitive surgery or radiation therapy."
"We are very pleased with this draft coverage determination. It is an important step toward ensuring that all prostate cancer patients covered by Medicare, which represents 50 percent of the population eligible for our test, have access to the unique biological information provided by Oncotype DX in order to more precisely assess their cancer's aggressiveness and for their physicians to determine the optimal treatment," said Kim Popovits, chairman of the board, chief executive officer and president of Genomic Health.
Todays PR - UCSF-led Study Shows Oncotype DX(R) and MRI May Provide Independent Information in Favorable Risk Prostate Cancer Presentation at American Urological Association 2015 Annual Meeting Reconfirms Oncotype DX Genomic Prostate Score as Independent Predictor of Adverse Pathology
For the first time, we looked at the association between information provided by a genomic assay and a prostate MRI to better understand the value these two technologies bring to clinical practice," said Michael Leapman, M.D., lead investigator from UCSF. "These new data show that, in some patients, further risk stratification may be possible, and tools such as GPS may add important biological information to more precisely assess the aggressiveness of a patient's cancer."